AbbVie rolls out $16.7B bond issue; Reported Pfizer target Sobi beats profit expectations;

@FiercePharma: It's all about that data as IBM Watson Health teams up with J&J, Cleveland Clinic and more. Article | Follow @FiercePharma

@EricPFierce: MHRA concerned with lack of testing by Relonchem , which is owned by India's Marksans Pharma. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI: Merck or Merck KGaA? German Merck beefs up branding to (hopefully) end confusion. Article | Follow @CarlyHFierce

> AbbVie ($ABBV) launched a $16.7 billion bond offering to help finance its proposed $21 billion buyout of Pharmacyclics. Report

> The Swedish drugmaker Sobi, rumored to be a Pfizer ($PFE) acquisition target, beat analyst expectations for quarterly profits at 172 million Swedish crowns, or $20.9 million. Report

> The European Medicines Agency tightened up rules on "revolving door" jobs for any of its expert committee members moving into industry. Report

> The U.S. Supreme Court declined to hear a case attempting to revive patent protection for Bristol-Myers Squibb's ($BMY) hepatitis B drug Baraclude. Report

> U.S.-based generics maker Mylan ($MYL) rolled out its version of the Teva ($TEVA) contraceptive pill Seasonale. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Abiomed gains on strong Impella revenue, with U.S. sales ramp to come after recent FDA approval. Article | Follow @FierceMedDev

@EmilyWFierce: Mayne Pharma beefs up U.S. sales ops to revive acne-fighter Doryx. FiercePharmaMarketing report | Follow @EmilyWFierce

> Dozens of hospitals to deploy IBM's Watson computer in fight against cancer. Story

> EndoChoice files for up to $115M IPO to back its wider-view Fuse endoscopy system. Article

Biotech News

@FierceBiotech: Ebola outbreak spurs a new antibody screening project at Theraclone. More from FierceBiotechResearch | Follow @FierceBiotech

@JohnCFierce: If Big Pharma takes over Kendall Sq the biotechs are going to have to move somewhere else. What's the new Brooklyn in Boston? | Follow @JohnCFierce

> Kymab pockets $50M from some A-list U.K. backers. Story

> Adaptimmune hauls in $191M in an upsized immuno-oncology IPO. Article

> Alexion scoops up a rare-disease blockbuster in $8.4B Synageva buyout. Report

Biotech Research News

> Scientists highlight link between diabetes and Alzheimer's. Item

> Microparticles amp up the effect of breast cancer vaccines. More

> Johns Hopkins team finds a new drug target for diabetes. Story

> UNC researchers hijack natural 'bubbles' to transport Parkinson's med. Article

> Rodent study once again spotlights role of arginase in hypertension. Report

Diagnostics News

> Abbott grabs FDA OK for early pregnancy blood test. Report

> Myriad Genetics stumbles as rivals flood BRCA market. More

> OpGen sees its shares fall 20% in IPO. Story

> Agilent acquires maker of software for diagnostics laboratories. Article

> RainDance Technologies and Pacific Biosciences partner for whole genome assembly. Item

Pharma Marketing News

> GSK's U.S. Advair sales plummet 22% in Q1--and that's without generics. Item

> The Q1 drug launch scorecard, starring Sanofi, Lilly, Pfizer, Gilead, Merck and more. Report

> Merck or Merck KGaA? German Merck beefs up branding to (hopefully) end confusion. More

> Mayne Pharma bolsters U.S. sales ops to revive acne-fighter Doryx. Article

> It's all about that data as IBM Watson Health teams up with J&J, Cleveland Clinic and more. Story

And Finally... Housecalls? There's an app for that. Report

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.